Leapfrog Bio
Founded 2019 · 1 known investors
Leapfrog develops precision cancer therapies by using its OncoSLX platform to identify genetic vulnerabilities in cancers driven by loss-of-function mutations and repurposing clinical-stage drugs against them. Its lead candidate, LFB190, is a BET inhibitor targeting EP300 loss-of-function mutant cancers, with additional programs including PIK3CA mutant cancers.
AI & Machine LearningBiotechHealthtech
Investors · 1
Frequently asked questions
- What does Leapfrog Bio do?
- Leapfrog develops precision cancer therapies by using its OncoSLX platform to identify genetic vulnerabilities in cancers driven by loss-of-function mutations and repurposing clinical-stage drugs against them. Its lead candidate, LFB190, is a BET inhibitor targeting EP300 loss-of-function mutant cancers, with additional programs including PIK3CA mutant cancers.
- Who are Leapfrog Bio's investors?
- Leapfrog Bio's investors include Two Bear Capital.